Inosine pranobex

Identification

Name
Inosine pranobex
Accession Number
DB13156
Description

Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 1115.249
Monoisotopic: 1114.554641092
Chemical Formula
C52H78N10O17
Synonyms
  • IAD
  • Inosine acedobene dimepranol
  • Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
  • Inosiplex
  • Isoprinosine
  • Methisoprinol
External IDs
  • NP-113
  • NPT-10381

Pharmacology

Indication

Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.

Mechanism of action

Inosine pranobex stimulates cell-mediated immune processes to viral infections.

Absorption

Rapidly absorbed from GIT

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Via urine

Half-life

50 min

Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

Mouse LD50 (Intravenous ): 1570 mg/kg Muse LD50 (Oral) : 9410mg/kg Mouse LD50 (subcutaneous) ; 2960mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcarboseAcarbose may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
No interactions found.

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ImunovirTabletOralKora Healthcare2000-01-25Not applicableCanada flag
IsoprinosineTabletOralNewport Pharmaceuticals International1997-06-052000-02-04Canada flag
Isoprinosine Tab 500mgTabletOralSystemed Inc.1993-12-311996-09-10Canada flag
Isoprinosine Tab 500mgTabletOralNewport Pharms International Inc.1983-12-311996-09-10Canada flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more

Categories

ATC Codes
J05AX05 — Inosine pranobex
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Not Available
Direct Parent
Purine nucleosides
Alternative Parents
Glycosylamines / 6-oxopurines / Pentoses / Hypoxanthines / Benzoic acids / Benzoyl derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans
show 14 more
Substituents
1,2-aminoalcohol / 6-oxopurine / Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzoic acid / Benzoic acid or derivatives
show 38 more
Molecular Framework
Not Available
External Descriptors
Not Available

Chemical Identifiers

UNII
W1SO0V223F
CAS number
36703-88-5
InChI Key
YLDCUKJMEKGGFI-KSIULYHRSA-N
InChI
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;3*5-/m1...111/s1
IUPAC Name
tris((2R)-1-(dimethylamino)propan-2-ol); tris(4-acetamidobenzoic acid); 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
SMILES
C[[email protected]@H](O)CN(C)C.C[[email protected]@H](O)CN(C)C.C[[email protected]@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[[email protected]]1O[[email protected]]([[email protected]](O)[[email protected]@H]1O)N1C=NC2=C1N=CNC2=O

References

General References
  1. ChemIDplus [Link]
  2. Pubchem [Link]
KEGG Drug
D01995
PubChem Compound
131704326
PubChem Substance
347829266
ChemSpider
58829622
RxNav
6048
Wikipedia
Inosine_pranobex
AHFS Codes
  • 08:18.00 — Antivirals
  • 08:18.92 — Miscellaneous Antivirals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Not Yet RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)1
3Not Yet RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19) / Respiratory Tract Infections (RTI)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphatic Diseases3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral
SyrupOral
TabletOral500 mg
SyrupOral5 g
Tablet
CreamTopical10 %
CreamTopical20 %
GranuleOral1 g
Granule, for solutionOral1 G
InjectionIntramuscular; Intravenous1 g/5ml
InjectionIntramuscular; Intravenous500 mg/5ml
InsertVaginal1500 mg
Syrup5 %
Tablet500 MG
Tablet750 MG
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-2.5ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)8.93ChemAxon
pKa (Strongest Basic)0.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area129.2 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity61.33 m3·mol-1ChemAxon
Polarizability24.6 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on December 03, 2016 17:28 / Updated on October 25, 2020 09:16

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates